Whole Genome DNA and RNA Sequencing of Whole Blood Elucidates the Genetic Architecture of Gene Expression Underlying a Wide Range of Diseases.
Whole Genome DNA and RNA Sequencing of Whole Blood Elucidates the Genetic Architecture of Gene Expression Underlying a Wide Range of Diseases.
复制标题
全血的全基因组 DNA 和 RNA 测序阐明了多种疾病背后的基因表达的遗传结构。
DOI:
10.1101/2022.04.13.22273841
复制
发表时间:
2022
期刊:
影响因子:
--
通讯作者:
Pelos
中科院分区:
文献类型:
--
作者:
Liu,Chunyu;Joehanes,Roby;Ma,Jiantao;Wang,Yuxuan;Sun,Xianbang;Keshawarz,Amena;Sooda,Meera;Huan,Tianxiao;Hwang,Shih-Jen;Bui,Helena;Tejada,Brandon;Munson,PeterJ;Cumhur,Demirkale;Heard-Costa,NancyL;Pitsillides,AchilleasN;Pelos
To create a scientific resource of expression quantitative trail loci (eQTL), we conducted a genome-wide association study (GWAS) using genotypes obtained from whole genome sequencing (WGS) of DNA and gene expression levels from RNA sequencing (RNA-seq) of whole blood in 2622 participants in Framingham Heart Study. We identified 6,778,286cis-eQTL variant-gene transcript (eGene) pairs atp< 5 × 10–8(2,855,111 uniquecis-eQTL variants and 15,982 unique eGenes) and 1,469,754trans-eQTL variant-eGene pairs atp< 1e−12 (526,056 uniquetrans-eQTL variants and 7233 unique eGenes). In addition, 442,379cis-eQTL variants were associated with expression of 1518 long non-protein coding RNAs (lncRNAs). Gene Ontology (GO) analyses revealed that the top GO terms forcis-eGenes are enriched for immune functions (FDR < 0.05). Thecis-eQTL variants are enriched for SNPs reported to be associated with 815 traits in prior GWAS, including cardiovascular disease risk factors. As proof of concept, we used this eQTL resource in conjunction with genetic variants from public GWAS databases in causal inference testing (e.g., COVID-19 severity). After Bonferroni correction, Mendelian randomization analyses identified putative causal associations of 60 eGenes with systolic blood pressure, 13 genes with coronary artery disease, and seven genes with COVID-19 severity. This study created a comprehensive eQTL resource via BioData Catalyst that will be made available to the scientific community. This will advance understanding of the genetic architecture of gene expression underlying a wide range of diseases.